Work

Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial

Year: 2009

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2009.27.15_suppl.8063

Authors: P. A. Janne, K. Reckamp, M. Koczywas, J. A. Engelman, D. R. Camidge, A. Rajan, F. Khuri, J. Q. Liang, J. O'Connell, G. Giaccone

Institutions: City Of Hope National Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, National Cancer Institute, Winship Cancer Institute, University of Colorado Denver

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2280282336

Cites:

Cited by: 41

Related to: 10